2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T937,Voretigene neparvovec (VN) marketed as Luxturna (Novartis Europharm Ltd) is the first approved gene therapy for severe RPE65-related retinal dystrophy, showing low-luminance vision improvement in adult trials. Low-luminance tests pose challenges for children, but pattern visual evoked potentials (VEPs) need minimal cooperation and provide objective measures of visual activation of the striate cortex. In this study, VN outcomes in young children were assessed using pattern VEPs in addition to standard measures. To evaluate vision outcomes and complications after VN treatment in children. This was a retrospective case series of children receiving VN from February 2020 to December 2023. Children with biallelic pathogenic variants in RPE65 were recruited from Great Ormond Street Hospital, a single-center, UK specialist pediatric hospital. Treatment with VN, a recombinant adeno-associated virus vector-based gene therapy. Pretreatment and posttreatment pattern VEPs, visual acuity (VA), full-field stimulus test (FST), optical coherence tomography (OCT) measures, and ocular complications. A total of 14 pediatric patients (27 eyes) were included in this analysis. Median (IQR) age at treatment of 9 female (64.3%) and 5 male (35.7%) patients was 6.88 (3.27-8.83) years, with a median (IQR) follow-up of 3.42 (2.65-4.08) years. VA improved from logMAR 1.00 to 0.76 (difference, -0.24). When 4 off-chart VA conversions were excluded, the change was less than 1 line, -0.03 (pretreatment, logMAR 0.74 [20/100] to posttreatment, 0.71 [20/100]). Only 3 eyes of 14 children (11%) completed a reliable full-field stimulus test, showing a mean (SD) 20.6 (14.8) dB. All 10 tested patients completed pattern VEPs; 7 showed clinically meaningful improvement, 2 worsened with chorioretinal atrophy, and 1 remained unchanged. Complications included transient inflammation (5 of 14 patients [35.7%]) and localized atrophy (6 of 14 patients [42.9%]). This case series study reports VN-treated patients as young as 15 months, confirming visual improvements, although not necessarily VA when off-chart VA conversions were excluded, consistent with previously reported outcomes. Pattern VEPs provided an objective measure of retinogeniculostriate recovery, supporting their use as an outcome measure in future trials for young children with inherited retinal diseases.31:Tf0f, Importance Voretigene neparvovec (VN) marketed as Luxturna (Novartis Europharm Ltd) is the first approved gene therapy for severe RPE65 -related retinal dystrophy, showing low-luminance vision improvement in adult trials. Low-luminance tests pose challenges for children, but pattern visual evoked potentials (VEPs) need minimal cooperation and provide objective measures of visual activation of the striate cortex. In this study, VN outcomes in young children were assessed using pattern VEPs in addition to standard measures. Objective To evaluate vision outcomes and complications after VN treatment in children. Design, Setting, and Participants This was a retrospective case series of children receiving VN from February 2020 to December 2023. Children with biallelic pathogenic variants in RPE65 were recruited from Great Ormond Street Hospital, a single-center, UK specialist pediatric hospital. Exposure Treatment with VN, a recombinant adeno-associated virus vector-based gene therapy. Main Outcomes and Measures Pretreatment and posttreatment pattern VEPs, visual acuity (VA), full-field stimulus test (FST), optical coherence tomography (OCT) measures, and ocular complications. Results A total of 14 pediatric patients (27 eyes) were included in this analysis. Median (IQR) age at treatment of 9 female (64.3%) and 5 male (35.7%) patients was 6.88 (3.27-8.83) years, with a median (IQR) follow-up of 3.42 (2.65-4.08) years. VA improved from logMAR 1.00 to 0.76 (difference, −0.24). When 4 off-chart VA conversions were excluded, the change was less than 1 line, −0.03 (pretreatment, logMAR 0.74 [20/100] to posttreatment, 0.71 [20/100]). Only 3 eyes of 14 children (11%) completed a reliable full-field stimulus test, showing a mean (SD) 20.6 (14.8) dB. All 10 tested patients completed pattern VEPs; 7 showed clinically meaningful improvement, 2 worsened with chorioretinal atrophy, and 1 remained unchanged. Complications included transient inflammation (5 of 14 patients [35.7%]) and localized atrophy (6 of 14 patients [42.9%]). Conclusions and Relevance This case series study reports VN-treated patients as young as 15 months, confirming visual improvements, although not necessarily VA when off-chart VA conversions were excluded, consistent with previously reported outcomes. Pattern VEPs provided an objective measure of retinogeniculostriate recovery, supporting their use as an outcome measure in future trials for young children with inherited retinal diseases. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"RPE65-Associated Retinal Dystrophy: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on RPE65-Associated Retinal Dystrophy (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/RPE65-Associated%20Retinal%20Dystrophy\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"RPE65-Associated Retinal Dystrophy\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/RPE65-Associated%20Retinal%20Dystrophy\"}]}}"}}]],["$","$L2f",null,{"title":"RPE65-Associated Retinal Dystrophy: Research & Clinical Takeaways","description":"Discover peer-reviewed research on RPE65-Associated Retinal Dystrophy with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1001/jamaophthalmol.2025.5505","pmid":"41481309","title":"Vision Outcomes in Children Treated With Voretigene Neparvovec for\n RPE65\n -Associated Retinopathy","journal_title":"JAMA Ophthalmology","journal_issn":"2168-6165","published_at":"2026-01-02T00:00:00.000Z","url":"https://doi.org/10.1001/jamaophthalmol.2025.5505","source_score":4,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-05","doi":"10.1001/jamaophthalmol.2025.5505","days":"14","issn":"2168-6165","rank":"7","field":"Clinical Medicine","score":"4","category":"Ophthalmology","categories":["Ophthalmology"],"_categories":["Ophthalmology"]},"pubmed":{"doi":"10.1001/jamaophthalmol.2025.5505","title":"Vision Outcomes in Children Treated With Voretigene Neparvovec for RPE65-Associated Retinopathy.","journal":"JAMA ophthalmology","methods":"","results":"A total of 14 pediatric patients (27 eyes) were included in this analysis. Median (IQR) age at treatment of 9 female (64.3%) and 5 male (35.7%) patients was 6.88 (3.27-8.83) years, with a median (IQR) follow-up of 3.42 (2.65-4.08) years. VA improved from logMAR 1.00 to 0.76 (difference, -0.24). When 4 off-chart VA conversions were excluded, the change was less than 1 line, -0.03 (pretreatment, logMAR 0.74 [20/100] to posttreatment, 0.71 [20/100]). Only 3 eyes of 14 children (11%) completed a reliable full-field stimulus test, showing a mean (SD) 20.6 (14.8) dB. All 10 tested patients completed pattern VEPs; 7 showed clinically meaningful improvement, 2 worsened with chorioretinal atrophy, and 1 remained unchanged. Complications included transient inflammation (5 of 14 patients [35.7%]) and localized atrophy (6 of 14 patients [42.9%]).","abstract":"$30","keywords":[],"pubmed_id":"41481309","conclusions":"","publication_date":"2026-01-02T00:00:00"},"crossref":{"DOI":"10.1001/jamaophthalmol.2025.5505","URL":"https://doi.org/10.1001/jamaophthalmol.2025.5505","ISSN":["2168-6165"],"link":[{"URL":"https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2842872/jamaophthalmology_thompson_2026_oi_250081_1765311758.33477.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Vision Outcomes in Children Treated With Voretigene Neparvovec for\n RPE65\n -Associated Retinopathy"],"author":[{"given":"Dorothy A.","family":"Thompson","sequence":"first","affiliation":[{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom"},{"name":"UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom"},{"name":"The Tony Kriss Visual Electrophysiology Unit, Department of Clinical and Academic Ophthalmology Sight and Sound Centre, London, United Kingdom"}]},{"given":"Elisabeth","family":"De Smit","sequence":"additional","affiliation":[{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom"},{"name":"The Tony Kriss Visual Electrophysiology Unit, Department of Clinical and Academic Ophthalmology Sight and Sound Centre, London, United Kingdom"}]},{"given":"Weijen","family":"Tan","sequence":"additional","affiliation":[{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom"},{"name":"The Tony Kriss Visual Electrophysiology Unit, Department of Clinical and Academic Ophthalmology Sight and Sound Centre, London, United Kingdom"}]},{"given":"Siân E.","family":"Handley","sequence":"additional","affiliation":[{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom"},{"name":"UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom"},{"name":"The Tony Kriss Visual Electrophysiology Unit, Department of Clinical and Academic Ophthalmology Sight and Sound Centre, London, United Kingdom"}]},{"given":"Oliver R.","family":"Marmoy","sequence":"additional","affiliation":[{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom"},{"name":"UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom"},{"name":"The Tony Kriss Visual Electrophysiology Unit, Department of Clinical and Academic Ophthalmology Sight and Sound Centre, London, United Kingdom"}]},{"given":"Robert H.","family":"Henderson","sequence":"additional","affiliation":[{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom"},{"name":"UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom"},{"name":"The Tony Kriss Visual Electrophysiology Unit, Department of Clinical and Academic Ophthalmology Sight and Sound Centre, London, United Kingdom"}]}],"issued":{"date-parts":[[2026,1,2]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-01-02T16:31:01Z","timestamp":1767371461000,"date-parts":[[2026,1,2]]},"indexed":{"date-time":"2026-01-02T16:34:16Z","timestamp":1767371656629,"date-parts":[[2026,1,2]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2842872"}},"subtitle":[],"deposited":{"date-time":"2026-01-02T16:31:03Z","timestamp":1767371463000,"date-parts":[[2026,1,2]]},"issn-type":[{"type":"print","value":"2168-6165"}],"published":{"date-parts":[[2026,1,2]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/j.ophtha.2021.03.031","key":"eoi250081r1","year":"2021","issue":"10","author":"Maguire","volume":"128","first-page":"1460","unstructured":null,"article-title":"Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease: phase 3 results at 3 and 4 years.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.3390/genes12081261","key":"eoi250081r2","year":"2021","issue":"8","author":"Huang","volume":"12","first-page":"1261","unstructured":null,"article-title":"Leber congenital amaurosis: current concepts of genotype-phenotype correlations.","journal-title":"Genes (Basel)","doi-asserted-by":"publisher"},{"DOI":"10.3390/ijms22137207","key":"eoi250081r3","year":"2021","issue":"13","author":"Aoun","volume":"22","first-page":"7207","unstructured":null,"article-title":"Inherited retinal diseases due to RPE65 variants: from genetic diagnostic management to therapy.","journal-title":"Int J Mol Sci","doi-asserted-by":"publisher"},{"DOI":"10.4274/tjo.galenos.2021.74944","key":"eoi250081r4","year":"2022","issue":"4","author":"Kahraman","volume":"52","first-page":"270","unstructured":null,"article-title":"Frequency of RPE65 gene mutation in patients with hereditary retinal dystrophy.","journal-title":"Turk J Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ajo.2018.09.024","key":"eoi250081r5","year":"2019","issue":null,"author":"Chung","volume":"199","first-page":"58","unstructured":null,"article-title":"The natural history of inherited retinal dystrophy due to biallelic mutations in the RPE65 gene.","journal-title":"Am J Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(17)31868-8","key":"eoi250081r6","year":"2017","issue":"10097","author":"Russell","volume":"390","first-page":"849","unstructured":null,"article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomized, controlled, open-label, phase 3 trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1167/iovs.08-2121","key":"eoi250081r7","year":"2008","issue":"10","author":"Jacobson","volume":"49","first-page":"4573","unstructured":null,"article-title":"Photoreceptor layer topography in children with Leber congenital amaurosis caused by RPE65 mutations.","journal-title":"Invest Ophthalmol Vis Sci","doi-asserted-by":"publisher"},{"DOI":"10.1101/cshperspect.a041278","key":"eoi250081r8","year":"2023","issue":"7","author":"Bennett","volume":"13","first-page":null,"unstructured":null,"article-title":"Overview of retinal gene therapy: current status and future challenges.","journal-title":"Cold Spring Harb Perspect Med","doi-asserted-by":"publisher"},{"DOI":"10.1111/ceo.13022","key":"eoi250081r9","year":"2018","issue":"3","author":"Chung","volume":"46","first-page":"247","unstructured":null,"article-title":"Novel mobility test to assess functional vision in patients with inherited retinal dystrophies.","journal-title":"Clin Exp Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41433-023-02636-3","key":"eoi250081r10","year":"2024","issue":"1","author":"Shi","volume":"38","first-page":"33","unstructured":null,"article-title":"Full-field stimulus threshold testing: a scoping review of current practice.","journal-title":"Eye (Lond)","doi-asserted-by":"publisher"},{"DOI":"10.1136/bjophthalmol-2015-308019","key":"eoi250081r11","year":"2016","issue":"11","author":"Hull","volume":"100","first-page":"1499","unstructured":null,"article-title":"Preserved visual function in retinal dystrophy due to hypomorphic RPE65 mutations.","journal-title":"Br J Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41433-024-03065-6","key":"eoi250081r12","year":"2024","issue":"13","author":"Testa","volume":"38","first-page":"2504","unstructured":null,"article-title":"Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice.","journal-title":"Eye (Lond)","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ajo.2010.08.047","key":"eoi250081r13","year":"2011","issue":"1","author":"Kempen","volume":"151","first-page":"7","unstructured":null,"article-title":"Appropriate use and reporting of uncontrolled case series in the medical literature.","journal-title":"Am J Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00417-008-0926-0","key":"eoi250081r14","year":"2009","issue":"1","author":"Lange","volume":"247","first-page":"137","unstructured":null,"article-title":"Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT).","journal-title":"Graefes Arch Clin Exp Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2007.06.047","key":"eoi250081r17","year":"2007","issue":"10","author":"Beck","volume":"114","first-page":"1804","unstructured":null,"article-title":"Visual acuity as an outcome measure in clinical trials of retinal diseases.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1167/iovs.02-1100","key":"eoi250081r18","year":"2003","issue":"8","author":"Rosser","volume":"44","first-page":"3278","unstructured":null,"article-title":"How sensitive to clinical change are ETDRS logMAR visual acuity measurements?","journal-title":"Invest Ophthalmol Vis Sci","doi-asserted-by":"publisher"},{"DOI":"10.1111/aos.14938","key":"eoi250081r19","year":"2022","issue":"3","author":"Marmoy","volume":"100","first-page":"322","unstructured":null,"article-title":"An alternative electroretinography protocol for children: a study of diagnostic agreement and accuracy relative to ISCEV Standard electroretinograms.","journal-title":"Acta Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10633-022-09872-0","key":"eoi250081r20","year":"2022","issue":"3","author":"Robson","volume":"144","first-page":"165","unstructured":null,"article-title":"ISCEV Standard for full-field clinical electroretinography (2022 update).","journal-title":"Doc Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1097/00006982-200512000-00010","key":"eoi250081r21","year":"2005","issue":"8","author":"Fishman","volume":"25","first-page":"1014","unstructured":null,"article-title":"Short-term intervisit variability of ERG amplitudes in normal subjects and patients with retinitis pigmentosa.","journal-title":"Retina","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10633-025-10042-1","key":"eoi250081r22","year":"2025","issue":"2","author":"Šuštar Habjan","volume":"151","first-page":"97","unstructured":null,"article-title":"ISCEV Standard for Clinical Visual Evoked Potentials (2025 update).","journal-title":"Doc Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41433-021-01839-w","key":"eoi250081r23","year":"2023","issue":"1","author":"Rufai","volume":"37","first-page":"139","unstructured":null,"article-title":"Electrophysiological and fundoscopic detection of intracranial hypertension in craniosynostosis.","journal-title":"Eye (Lond)","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.oret.2021.11.005","key":"eoi250081r24","year":"2022","issue":"4","author":"Sengillo","volume":"6","first-page":"273","unstructured":null,"article-title":"Visual acuity, retinal morphology, and patients’ perceptions after voretigene neparovec-rzyl therapy for RPE65-associated retinal disease.","journal-title":"Ophthalmol Retina","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2016.03.003","key":"eoi250081r25","year":"2016","issue":"7","author":"Weleber","volume":"123","first-page":"1606","unstructured":null,"article-title":"Results at 2 years after gene therapy for RPE65-deficient Leber congenital amaurosis and severe early childhood–onset retinal dystrophy.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10633-020-09770-3","key":"eoi250081r26","year":"2021","issue":"1","author":"Hamilton","volume":"142","first-page":"25","unstructured":null,"article-title":"VEP estimation of visual acuity: a systematic review.","journal-title":"Doc Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1001/archophthalmol.2011.298","key":"eoi250081r27","year":"2012","issue":"1","author":"Jacobson","volume":"130","first-page":"9","unstructured":null,"article-title":"Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.","journal-title":"Arch Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.preteyeres.2022.101115","key":"eoi250081r28","year":"2023","issue":null,"author":"Stingl","volume":"92","first-page":null,"unstructured":null,"article-title":"Therapy with voretigene neparvovec: how to measure success?","journal-title":"Prog Retin Eye Res","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2023.09.006","key":"eoi250081r29","year":"2024","issue":"2","author":"Lorenz","volume":"131","first-page":"161","unstructured":null,"article-title":"Single center experience with voretigene neparvovec gene augmentation therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41598-022-22180-6","key":"eoi250081r30","year":"2022","issue":"1","author":"Testa","volume":"12","first-page":"17637","unstructured":null,"article-title":"Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65-related inherited retinal dystrophy.","journal-title":"Sci Rep","doi-asserted-by":"publisher"},{"DOI":"10.1167/iovs.65.14.30","key":"eoi250081r31","year":"2024","issue":"14","author":"Aleman","volume":"65","first-page":"30","unstructured":null,"article-title":"Retinal degeneration associated with biallelic RDH12 variants: longitudinal evaluation of retinal structure and visual function in pediatric patients.","journal-title":"Invest Ophthalmol Vis Sci","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10633-023-09952-9","key":"eoi250081r32","year":"2023","issue":"3","author":"Thompson","volume":"147","first-page":"147","unstructured":null,"article-title":"ISCEV Standard pattern reversal VEP development: pediatric reference limits from 649 healthy subjects.","journal-title":"Doc Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1159/000529777","key":"eoi250081r33","year":"2023","issue":"1","author":"Lorenz","volume":"66","first-page":"727","unstructured":null,"article-title":"Current management of patients with RPE65 mutation associated inherited retinal degenerations in Europe: results of a 2-year follow-up multinational survey.","journal-title":"Ophthalmic Res","doi-asserted-by":"publisher"},{"DOI":"10.1136/bjo-2024-326221","key":"eoi250081r34","year":"2025","issue":"2","author":"Daruich","volume":"109","first-page":"281","unstructured":null,"article-title":"12-Month outcomes after voretigene neparvovec gene therapy in paediatric patients with RPE65-mediated inherited retinal dystrophy.","journal-title":"Br J Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.oret.2021.03.016","key":"eoi250081r35","year":"2022","issue":"1","author":"Gange","volume":"6","first-page":"58","unstructured":null,"article-title":"Perifoveal chorioretinal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-mediated Leber congenital amaurosis.","journal-title":"Ophthalmol Retina","doi-asserted-by":"publisher"},{"DOI":null,"key":"eoi250081r36","year":"2024","issue":"7","author":"Fischer","volume":"65","first-page":"3290","unstructured":null,"article-title":"Real-world safety and effectiveness of voretigene neparvovec: year 3 interim results from the PERCEIVE study.","journal-title":"Invest Ophthalmol Vis Sci","doi-asserted-by":null},{"DOI":"10.3390/biom13101484","key":"eoi250081r37","year":"2023","issue":"10","author":"Kiraly","volume":"13","first-page":"1484","unstructured":null,"article-title":"Outcomes and adverse effects of voretigene neparvovec treatment for biallelic RPE65-mediated inherited retinal dystrophies in a cohort of patients from a single center.","journal-title":"Biomolecules","doi-asserted-by":"publisher"},{"DOI":"10.1007/s10633-011-9267-0","key":"eoi250081r38","year":"2011","issue":"3","author":"Mellow","volume":"122","first-page":"133","unstructured":null,"article-title":"The reproducibility of binocular pattern reversal visual evoked potentials: a single subject design.","journal-title":"Doc Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamapediatrics.2022.3181","key":"eoi250081r39","year":"2022","issue":"11","author":"Lei","volume":"176","first-page":"1131","unstructured":null,"article-title":"Core outcome sets in child health: a systematic review.","journal-title":"JAMA Pediatr","doi-asserted-by":"publisher"},{"DOI":"10.1097/IAE.0000000000004296","key":"eoi250081r40","year":"2025","issue":"2","author":"Simunovic","volume":"45","first-page":"286","unstructured":null,"article-title":"The Fight Inherited Retinal Blindness! Project: a new treatment outcome and natural history registry for inherited retinal disease.","journal-title":"Retina","doi-asserted-by":"publisher"},{"DOI":"10.3390/jcm13185512","key":"eoi250081r41","year":"2024","issue":"18","author":"Igoe","volume":"13","first-page":"5512","unstructured":null,"article-title":"Update on clinical trial endpoints in gene therapy trials for inherited retinal diseases.","journal-title":"J Clin Med","doi-asserted-by":"publisher"},{"DOI":null,"key":"eoi250081r15","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Bach? M. Visual acuity “cheat sheet” for high and low vision. Accessed February 6, 2024. https://michaelbach.de/sci/acuity.html","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"eoi250081r16","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Food & Drug Administration. Luxturna (voretigene neparvovec) subretinal injection approval letter. Accessed April 30, 2025. https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/December-19--2017-Approval-Letter---LUXTURNA.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Ophthalmology"],"reference-count":41,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,2]]},"references-count":41,"short-container-title":["JAMA Ophthalmol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamaophthalmol.2025.5505","is_oa":false,"title":"Vision Outcomes in Children Treated With Voretigene Neparvovec for\n RPE65\n -Associated Retinopathy","updated":"2026-01-03T00:50:51+00:00","published_date":"2026-01-02","best_oa_location":null}},"created_at":"2026-01-15T20:51:27.064Z","updated_at":"2026-01-16T11:56:46.634Z","tags":[{"paper_doi":"10.1001/jamaophthalmol.2025.5505","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5505","tag_type":"brand","value":"Luxturna","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5505","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5505","tag_type":"condition","value":"RPE65-Associated Retinal Dystrophy","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5505","tag_type":"generic","value":"voretigene neparvovec","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5505","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5505","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5505","tag_type":"modality","value":"Gene Therapy","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5505","tag_type":"sample_size","value":"n=14","value_numeric":14},{"paper_doi":"10.1001/jamaophthalmol.2025.5505","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5505","tag_type":"study_design","value":"Case Series","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5505","tag_type":"warning","value":"Primary outcome not specified; multiple outcomes summarized.","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2025.5505","tag_type":"warning","value":"The 11% figure for FST completion references eyes and may not align cleanly with patient counts.","value_numeric":null}],"summaries":{"what_studied":"Retrospective case series at a single UK pediatric center evaluating children with biallelic RPE65 variants treated with voretigene neparvovec from February 2020 to December 2023, using pattern VEPs, visual acuity, FST, OCT, and complications over a median 3.42-year follow-up.","key_result":"Visual acuity shifted from logMAR 1.00 to 0.76; excluding four off‑chart conversions, change was −0.03 (0.74 to 0.71). All 10 tested completed pattern VEPs: 7 improved, 2 worsened with chorioretinal atrophy, 1 was unchanged; only 3 eyes (11%) had reliable FST (mean [SD] 20.6 [14.8] dB); complications included transient inflammation in 5/14 (35.7%) and localized atrophy in 6/14 (42.9%).","limitations":"Single-center retrospective case series with small sample (n=14) and incomplete functional testing (reliable FST in only 3 eyes). VA outcomes were sensitive to off‑chart conversions; excluding them yielded less than a 1‑line change.","practice_takeaway":"In young children with RPE65 retinopathy treated with voretigene neparvovec, pattern VEPs captured objective visual pathway gains even when VA gains were modest. Monitor for postoperative inflammation and localized chorioretinal atrophy."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"RPE65-Associated Retinal Dystrophy"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"RPE65-Associated Retinal Dystrophy"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"RPE65-Associated Retinal Dystrophy"}}}]]

Papers